Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility

ABO mismatch between donor and recipient occurs in 40% of allogeneic hematopoietic stem cell transplantations (HCT). Different strategies have been described to reduce isohemagglutinins (IHA) before HCT. We describe the effect of selective ABO immunoadsorption (ABO IA) on erythrocyte transfusion rate and the development of post‐transplant pure red cell aplasia (ptPRCA).

[1]  R. Oberbauer,et al.  Antigen-Specific Immunoadsorption With the Glycosorb® ABO Immunoadsorption System as a Novel Treatment Modality in Pure Red Cell Aplasia Following Major and Bidirectional ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation , 2020, Frontiers in Medicine.

[2]  S. Montoto,et al.  The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus , 2020, Bone Marrow Transplantation.

[3]  S. Aksu,et al.  Impact of ABO blood group incompatibility on the outcomes of allogeneic hematopoietic stem cell transplantation. , 2020, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[4]  T. Coates.  Iron overload in transfusion-dependent patients. , 2019, Hematology. American Society of Hematology. Education Program.

[5]  A. Mehrabi,et al.  Outcomes and complications following ABO‐incompatible kidney transplantation performed after desensitization by semi‐selective immunoadsorption ‐ a retrospective study , 2019, Transplant international : official journal of the European Society for Organ Transplantation.

[6]  U. Germing,et al.  Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation , 2019, Bone Marrow Transplantation.

[7]  A. Nagler,et al.  Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia—an update on behalf of the ALWP of the EBMT , 2019, Bone Marrow Transplantation.

[8]  J. Connors,et al.  Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation. , 2018, The New England journal of medicine.

[9]  G. Tamaddon,et al.  ABO Blood Grouping Mismatch in Hematopoietic Stem Cell Transplantation and Clinical Guides , 2018, International journal of hematology-oncology and stem cell research.

[10]  K. Nomura,et al.  Immunoadsorption in neurological disorders. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[11]  M. Aringer,et al.  Immunoadsorption in Autoimmune Diseases Affecting the Kidney. , 2017, Seminars in nephrology.

[12]  M. MacMillan,et al.  Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  D. Allan,et al.  Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials , 2016, Transfusion.

[14]  N. Özbek,et al.  ABO blood group mismatched hematopoietic stem cell transplantation. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[15]  Nina Worel,et al.  ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation , 2015, Transfusion Medicine and Hemotherapy.

[16]  H. Pavenstädt,et al.  Antigen-Specific versus Non-Antigen-Specific Immunoadsorption in ABO-Incompatible Renal Transplantation , 2015, PloS one.

[17]  T. Fehr,et al.  The Reuse of Immunoadsorption Columns in ABO-Incompatible Kidney Transplantation Is Efficient: The Swiss Experience , 2015, Transplantation.

[18]  G. Kobbe,et al.  Treatment of donor-specific antibody-mediated graft rejection by immunochemotherapy, third-party DLI, plasmapheresis and immunoadsorption , 2015, Bone Marrow Transplantation.

[19]  S. Parmar,et al.  Incidence and natural history of pure red cell aplasia in major ABO‐mismatched haematopoietic cell transplantation , 2013, British journal of haematology.

[20]  T. Fehr,et al.  Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  S. Durrant,et al.  Outcomes after major or bidirectional ABO‐mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor‐type secretor plasma with or without plasma exchange , 2012, Transfusion.

[22]  M. Robin,et al.  Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  A. Gratwohl,et al.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins , 2009, Haematologica.

[24]  M. Hirokawa,et al.  Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program , 2008, Haematologica.

[25]  J. Bourhis,et al.  Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. , 2008, Experimental hematology.

[26]  G. Helbig,et al.  Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies , 2007, Annals of Hematology.

[27]  G. Tydén,et al.  Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies , 2006, Transfusion.

[28]  A. Barrett,et al.  ABO blood group barrier in allogeneic bone marrow transplantation revisited. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  W. Berdel,et al.  The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation , 2005, Transfusion.

[30]  G. Helbig,et al.  Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. , 2005, Haematologica.

[31]  Y. Chalandon,et al.  Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion , 2004, European journal of haematology.

[32]  M. Ueda,et al.  Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease , 2002, Bone Marrow Transplantation.

[33]  A. Barrett,et al.  Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. , 2001, Blood.

[34]  S. Rowley.  Hematopoietic stem cell transplantation between red cell incompatible donor–recipient pairs , 2001, Bone Marrow Transplantation.

[35]  S. Brunet,et al.  Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin , 1997, Bone Marrow Transplantation.

[36]  B. Labar,et al.  Antilymphocyte globulin for treatment of pure red cell aplasia after major ABO incompatible marrow transplant. , 1992, Bone marrow transplantation.